SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit

Rhea-AI Summary

SELLAS Life Sciences Group announced its participation in the JMP Securities Hematology and Oncology Summit, a virtual investor conference set for December 6-7, 2022. The CEO, Angelos Stergiou, will host a fireside chat on December 7 at 3:20 p.m. ET. SELLAS is focused on developing innovative cancer therapies, including their lead product candidate, GPS, which targets the WT1 protein in various tumor types. The company is also working on GFH009, a selective CDK9 inhibitor.

NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor conference being held from December 6-7, 2022. Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in a virtual fireside chat on Wednesday, December 7, 2022, at 3:20 p.m. ET.

For more information about the conference, please refer to the conference website or contact your JMP Securities representative directly.

About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements
Any statements in this press release or made during the investor conference referenced herein about SELLAS’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com

FAQ

What is the focus of SELLAS Life Sciences Group as of November 2022?

SELLAS Life Sciences Group is focused on developing novel therapies for various cancer indications.

When will SELLAS present at the JMP Securities Hematology and Oncology Summit?

SELLAS will present at the JMP Securities Hematology and Oncology Summit on December 6-7, 2022.

What is the lead product candidate of SELLAS Life Sciences Group?

The lead product candidate of SELLAS is GPS, which targets the WT1 protein found in a variety of tumors.

Who will represent SELLAS at the investor conference?

Angelos Stergiou, CEO of SELLAS, will represent the company during the investor conference.

What time is the fireside chat with SELLAS CEO?

The fireside chat with CEO Angelos Stergiou is scheduled for December 7, 2022, at 3:20 p.m. ET.

What is GFH009 in relation to SELLAS Life Sciences Group?

GFH009 is a small molecule CDK9 inhibitor being developed by SELLAS for various therapeutic uses.